Categories
Uncategorized

Erenumab

A monoclonal antibody

Pregnancy category AU: B1

Routes of administration-Subcutaneous injection

Bioavailability 82%

Metabolism Proteolysis

Elimination half-life 28 days

The first CGRPR antagonist to be approved by the U.S. Food and Drug Administration.

Erenumab is indicated for the prevention of migraine in adults.

Side effects: constipation, pruritus, muscle spasms, as well as mild and mostly transient reactions at the injection site.

Erenumab is a fully human monoclonal antibody blocking the calcitonin gene-related peptide receptor (CGRPR).

The medication significantly reduced the number of migraine days per month by 3.2 in the 70-mg group and 3.7 in the 140-mg group, versus 1.8 in the placebo (0-mg) group.

 

Leave a Reply

Your email address will not be published. Required fields are marked *